Abstract
Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
CNS & Neurological Disorders - Drug Targets
Title:Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders
Volume: 12 Issue: 5
Author(s): Shafiqur Rahman
Affiliation:
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
Abstract: Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Export Options
About this article
Cite this article as:
Rahman Shafiqur, Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders, CNS & Neurological Disorders - Drug Targets 2013; 12(5) . https://dx.doi.org/10.2174/1871527311312050011
DOI https://dx.doi.org/10.2174/1871527311312050011 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews The Potential of Serratiopetidase and Lumbrokinase for the Degradation of Prion Peptide 106-126 - an <i>In Vitro</i> and <i>In Silico</i> Perspective
CNS & Neurological Disorders - Drug Targets Interleukin-1 Drives Cerebrovascular Inflammation via MAP Kinase-Independent Pathways
Current Neurovascular Research Parkinson’s Disease: A Review from Pathophysiology to Treatment
Mini-Reviews in Medicinal Chemistry Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Autophagic Dysfunction in Dementia: Scope for Development of Potential Remedies
CNS & Neurological Disorders - Drug Targets Development of Neurochemical Normalization (“Agonist Substitution”) Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909
Current Medicinal Chemistry - Central Nervous System Agents Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk
Current Drug Abuse Reviews Novel Modular DNA Aptamer for Human Thrombin with High Anticoagulant Activity
Current Medicinal Chemistry Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Meet Our Editorial Board Member
Current Protein & Peptide Science Neuronal Nicotinic Acetylcholine Receptor Agonists: Pharmacophores, Evolutionary QSAR and 3D-QSAR models
Current Topics in Medicinal Chemistry Are Descending Control Pathways of the Lower Urinary Tract and Pain Overlapping Systems?
Central Nervous System Agents in Medicinal Chemistry Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches
CNS & Neurological Disorders - Drug Targets Neuroendocrine Response to Psychosocial Stressors, Inflammation Mediators and Brain-periphery Pathways of Adaptation
Central Nervous System Agents in Medicinal Chemistry The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Conference Report (3<sup>rd</sup> GTC Congress Report on Ubiquitin & Drug Discovery Feb 25-26, Palms Casino Resort, Las Vegas, NV, USA)
CNS & Neurological Disorders - Drug Targets The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis
Current Pharmaceutical Design Neurotransmitters and Behavioral Alterations Induced by Nickel Exposure
Endocrine, Metabolic & Immune Disorders - Drug Targets